Quality in multimodal pain management. Descending inhibition as an objective parameter of the quality of treatment.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006850

Enrollment

280

Registered

2018-04-10

Start date

2015-04-27

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OPS 8-918.X (in-patient Multimodal pain therapie) R52.2

Interventions

Group 1: Patients with chronic pain undergoing an inpatient multimodal pain treatment program in the Asklepios Medical Center North - Heidberg Measurements pre- and post Treatment: Primary outcome par

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Informed consent, age = 18 years, negative pregnancy test for women of reproductive age, sexually active women have to pe post-menopausal, chirurgically sterilized or using an effective method of contraception (e.g. prescribed oral contraceptives, contraceptive injections, IUD, hormone patches, sterilization of male sexual partner), adequate communicative abilities (naming and distinguishing pain localization and intensity, completing questionnaires), positive admission criteria for MMST (OPS 8-981.0), participation in inpatient MMST in the Asklepios Medical Center North - Heidberg

Exclusion criteria

Exclusion criteria: Insufficient language skills, cognitive impairment, pregnancy or lactation, non-classifiable pain syndrome

Design outcomes

Primary

Measure	Time frame
1. Improvement of descending inhibition through therapy in terms of an increase of the CPM-score, measured pre- and post treatment. Checked upon after the last patient has been treated. 2. CPM differentiation as prognostic factor on the outcome of the multimodal pain therapy. Group-difference (pathologic vs. physiologic CPM in t0) of pain (NRS), Qualitity of life (SF-12) or Global Impression of Change over Treatment-Phase (measured pre- and post treatment). Checked upon after the last patient has been treated.	—

Measure

Time frame

1. Improvement of descending inhibition through therapy in terms of an increase of the CPM-score, measured pre- and post treatment. Checked upon after the last patient has been treated. 2. CPM differentiation as prognostic factor on the outcome of the multimodal pain therapy. Group-difference (pathologic vs. physiologic CPM in t0) of pain (NRS), Qualitity of life (SF-12) or Global Impression of Change over Treatment-Phase (measured pre- and post treatment). Checked upon after the last patient has been treated.

—

Secondary

Measure	Time frame
1. Improvement of the subjective measurement Points (measured pre- and post Treatment). Check upon after the last Patient has been treated. 2. Sustainability of Treatment achivement (measurements of subjective Parameters pre- post Treatment and 3 month follow-up). Checked upon after last patients follow-up time.	—

Countries

Germany

Contacts

Public ContactFlorian Sophus Lienau

Asklepios Klinik Nord, BT HeidbergNeurozentrum undZentrum für interdisziplinäre Schmerztherapie

f.lienau@asklepios.com+49 40 18 18 87 30 76

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026